Expert Review of Hematology

Papers
(The H4-Index of Expert Review of Hematology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review50
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma45
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis42
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma41
Advances in myelodysplastic syndromes: promising novel agents and combination strategies32
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary28
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis23
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly22
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms22
An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: ‘bridging the gap between laboratory data and patient related outcomes’20
Synovitis in hemophilia: preventing, detecting, and treating joint bleeds20
Post-COVID-19 hematologic complications: a systematic review20
Exploring health disparities in diagnosing multiple myeloma19
The promise of novel treatments for severe chronic neutropenia18
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?17
Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection16
0.055353879928589